Slideset on: Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the.

Slides:



Advertisements
Similar presentations
Funding of Cohort Studies Diana Finzi, Ph.D. Chief, Pathogenesis and Basic Research Branch Division of AIDS National Institutes of Health Bethesda, Maryland,
Advertisements

Mortality and causes of death among women living with HIV in the UK in the era of highly-active antiretroviral therapy Sara Croxford, A Kitching, M Kall,
The Progression of Liver Fibrosis is Associated with the Severity of the HIV Disease in HIV-HCV Co-infected Female Patients Mohammad K. Mohammad 1, Babu.
1 Lauren E. Finn, 2 Seth Sheffler-Collins, MPH, 2 Marcelo Fernandez-Viña, MPH, 2 Claire Newbern, PhD, 1 Dr. Alison Evans, ScD., 1 Drexel University School.
NCD Complications in HIV Patients Esteban Martinez Hospital Clínic University of Barcelona Barcelona SPAIN Washington D.C., USA,
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER HIV and Non Hodgkin Lymphoma Virginia C. Broudy, MD September 25, 2014 Presentation prepared by: Presenter.
World Burden of Cancer Epi 242 Cancer Epidemiology Binh Goldstein, Ph.D. October 7, 2009.
HIV and Cancer Sarah Wilcox Jan Case Report 36 yr old lady 36 yr old lady HIV +ve for 3 years (husband diagnosed at the same time) HIV +ve for 3.
HSTAT1101: 27. oktober 2004 Odd Aalen
Overview of All SEER-Medicare Publications Through 2012 Mark D. Danese, MHS, PhD July 24, 2012.
Seroprevalence of HBV and HCV among Children in the Kilimanjaro Region, Tanzania Florida J. Muro, Suzanne P. Fiorillo, Christopher Odhiambo, Coleen K.
Causes of Death and Mortality Trends among Utah HIV/AIDS Cases, Anne Burke, MS, Matthew S. Mietchen, MPH, David Jackson, MPH, Allyn K. Nakashima,
Health Consultation: Evaluation of Cancer Incidence in Census Tracts of Attleboro and Norton, Massachusetts: Suzanne K. Condon Associate Commissioner.
Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. Eng C1, Rogers J2, Chang GJ3, You N3, Das P4, Rodriguez-Bigas.
The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected.
Assessing the Response to Hepatitis B Immunizations in HIV-Positive Adults: Results from the 550 Clinic cohort study Camila Calderon 1, Anupama Raghuram.
Aging and HIV Steven C. Zell, M.D. Professor of Medicine AAHIVS Nevada AIDS Education and Training Center University of Nevada School of Medicine.
Should We be Measuring Mortality in HIV Clinical Programs? September 13 th, 2012 Steven Johnson MD Director, University of Colorado HIV/AIDS Clinical Program;
Risk of Osteoporotic Fractures Associated with Cumulative Exposure to Tenofovir and Other Antiretroviral Agents Roger Bedimo, MD; Song Zhang, PhD; Henning.
Nguyen ML, Sumbry A, Reddy D, Harvey K, Gunthel C, Wang W, Tsui C, Ziemer D, del Rio C, Young JL Increased Incidence of Non AIDS-related Malignancies and.
Risk Factors for Development of Anal Cancer in HIV-Infected Men Phillip Cole, M.D. 1, Wendy Leyden, M.P.H. 2, Michael Silverberg, Ph.D., M.P.H. 2 1 UC.
STRATEGIE THERAPEUTIQUE JL Meynard Hôpital Saint-Antoine PARIS.
A Glimpse of the Science Behind the American Cancer Society Access to Care Campaign Impact of Being Uninsured or Underinsured on Individuals with Cancer.
Alaska Native Tumor Registry Alaska Native Epidemiology Center 40-Year Trends in Cancer Incidence among Alaska Native People
Impact of Highly Active Antiretroviral Therapy on the Incidence of HIV- encephalopathy among perinatally- infected children and adolescents. Kunjal Patel,
David Dowdy, Elvin Geng, Katerina Christopoulos, James Kahn, C. Bradley Hare, Daniel Wlodarczyk, Diane Havlir Internal Medicine Residency Program, UCSF.
CANCER CONTROL NHPA’s. What is it? Cancer is a term to describe a diverse group of diseases in which some of the cells in body become defective. The following.
Lipoatrophy and lipohypertrophy are independently associated with hypertension: the effect of lipoatrophy but not lipohypertrophy on hypertension is independent.
Adolescent and Young Adult Oncology Scientific Meeting 2013 Epidemiology Working Group.
Associated Web sites CustomizableMaps The Atlas On-Line.
Changing Epidemiology of Opportunistic Infections in the HAART Era International AIDS Society 2012 Henry Masur MD Chief, Critical Care Medicine Department.
Tools to Access the Latest Cancer Statistics Paul Miller Washington Reporting Fellowships program presentation April 15, 2013.
Use of Single Data Source Can Significantly Underestimate Hepatitis C Mortality Rates Slideset on: Wu C, Chang HG, McNutt LA, Smith PF. Estimating the.
Arthritis Advisory Committee March 4, 2003 Update on the Safety of TNF Blockers Li-ching Liang, M.D. FDA / CBER/ OTRR Arthritis Advisory Committee March.
Breast cancer affects 1 in 8 women during their lives. 1 Population Statistics.
FRENCH high-resolution studies - Breast cancer: 1990, 1997, 2003, 2010 ? - Colorectal cancer: 1990, 1995, 2000, 2005, 2010 ? - Prostate cancer: 1995,
Weekly Alendronate Safe and Effective at Increasing Bone Mineral Density in HIV-Infected Persons on Antiretroviral Therapy Slideset on: McComsey GA, Kendall.
Cancer Linkage With an HIV/STD Registry: Describing the Cancer Morbidity Among HIV/AIDS Patients and Opportunities for Improving Surveillance June 5, 2007.
Cancer in Ontario: Overview A Statistical Report.
What the cancer tools show for London Vivian Mak National Cancer Intelligence Network London Public Health Knowledge and Intelligence Network meeting Wednesday.
Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
Efavirenz Use Not Associated With Depressive Episodes, According to Analysis of Randomized Clinical Trial Outcomes Slideset on: Journot V, Chene G, De.
Changes in Cancer Mortality among HIV-Infected Patients : The Mortalité 2005 Survey Fabrice Bonnet, Christine Burty, Charlotte Lewden, Dominique Costagliola,
Problems of HIV Infection in the HAART Era Akihiko Suganuma M.D. Tokyo Metropolitan Komagome Hospital Department of Infectious Diseases.
Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:
POWER 3 Study Confirms Safety and Efficacy of Darunavir/Ritonavir in Treatment-Experienced Patients Slideset on: Molina JM, Cohen C, Katlama C, et al.
HIV Infection Increases Risk of ASCUS and Subsequent Development of SILs Slideset on: Duerr A, Paramsothy P, Jamieson DJ, et al. Effect of HIV infection.
Clinicaloptions.com/hepatitis NAFLD and NASH Prevalence in US Cohort Slideset on: Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty.
Reducing Tobacco Intake Lowers Risk of Lung Cancer in Heavy Smokers Slideset on: Godtfredsen NS, Prescott E, Osler M. Effect of smoking reduction on lung.
Slideset on: Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving.
R2. 최태웅 / Pf. 이미숙 The American Journal of Medicine, Vol 127, No 12, December 2014.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.
Increasing Tuberculosis Prevalence in South African Township Associated With Increasing HIV Prevalence Slideset on: Lawn SD, Bekker LG, Middelkoop K, Myer.
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
Campos M et al. Proc EHA 2013;Abstract B2009.
Campos M et al. Proc EHA 2013;Abstract B2009.
2 Incidence SABER This module presents statistics from Chapter 2: Incidence Ontario Cancer Statistics 2016 Chapter 2: Incidence.
Cancer Trends in North America Over the Past Decade
5 Prevalence ZEINAB This module presents statistics from Chapter 5: Prevalence Ontario Cancer Statistics 2016 Chapter 5: Prevalence.
Bronx Community Health Dashboard: Other Cancers Last Updated: 01/09/2018 See last slide for more information about this project.
Summary of Fire Fighter Cancer Cohort Studies
5 Prevalence Ontario Cancer Statistics 2016 Chapter 5: Prevalence.
Hepatitis C in the HIV-infected patient
Estimated current cancer incidence
Estimated current cancer mortality
7 Cancer prevalence Ontario Cancer Statistics 2018 Chapter 7: Cancer prevalence.
Literature Flow to Assess the Effects of Omega-3 Fatty Acid on Tumor Incidence Catherine H. MacLean, et al, JAMA. 2006; 295:
Citation: Cancer Care Ontario
Presentation transcript:

Slideset on: Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, Ann Intern Med. 2008;148: This program is supported by educational grants from Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC Non-AIDS–Defining Cancer Incidence Increased Among HIV-Infected Individuals vs General Population in Post-HAART Era

clinicaloptions.com/hiv Non-AIDS–Defining Cancers in Post-HAART Era Background  HIV-infected patient survival rate significantly improved by HAART –Decreased incidence of AIDS-defining infections and cancer –Longer patient survival linked with increase in several chronic conditions, eg, lipodystrophy, metabolic syndrome, osteopenia, cardiovascular disease, non-AIDS– defining cancers  Studies of non-AIDS–defining cancers in HIV-infected patients –Limited by population size and demographics –Lack of comparison to uninfected control patients –Fail to include patients at all HIV infection stages –Do not focus on trends in cancer incidence since advent of HAART  Present study compared cancer incidence rates from 2 large, prospective cohort studies of HIV-infected patients with those in the general population –Included all stages of HIV infection Patel P, et al. Ann Intern Med. 2008;148:

clinicaloptions.com/hiv Non-AIDS–Defining Cancers in Post-HAART Era Summary of Study Design  Cancer incidence estimated from combination of ASD [1] and HOPS [2] databases –Data not statistically different between studies, combined to better represented HIV- infected population than either study alone  Cancer incidence in HIV-infected cohorts compared with that in general population (derived from the [SEER program [3] )  Incidence rates determined for 3 observation periods [4] –Pre-HAART ( ) –Early HAART ( ) –Recent HAART ( )  Incidence rates reported as per 100,000 person-years 1. Farizo KM, et al. JAMA. 1992;267: Moorman AC, et al. Ann Epidemiol. 1999;9: National Cancer Institute. Available at: 4. Patel P, et al. Ann Intern Med. 2008;148:

clinicaloptions.com/hiv Non-AIDS–Defining Cancers in Post-HAART Era Main Findings Patel P, et al. Ann Intern Med. 2008;148: Cancer Type, Observed Rate per 100,000 Person-Yrs (95% CI) ASD/HOPS (157,819 Person-Yrs) SEER (334,802,121 Person-Yrs) SRR* (95% CI) Anal51.4 ( )1.5 ( )42.9 ( ) Vaginal33.9 ( )3.2 ( )21.0 ( ) Hodgkin’s lymphoma51.4 ( )3.3 ( )14.7 ( ) Liver31.7 ( )5.3 ( )7.7 ( ) Lung88.8 ( )67.5 ( )3.3 ( ) Melanoma24.7 ( )18.4 ( )2.6 ( ) Oropharyngeal33.0 ( )16.1 ( )2.6 ( ) Leukemia15.2 ( )12.2 ( )2.5 ( ) Colorectal47.0 ( )52.0 ( )2.3 ( ) Renal14.0 ( )13.0 ( )1.8 ( ) Prostate32.7 ( )173.5 ( )0.6 (0.4-08) *Calculated as ASD/HOPS to SEER populations.

clinicaloptions.com/hiv Non-AIDS–Defining Cancers in Post-HAART Era Main Findings (cont’d) Patel P, et al. Ann Intern Med. 2008;148: Cancer Type, SIR Per 100,000 Person-Yrs ASD/HOPS (157,819 Person-Yrs) P Value* AIDS-defining cancers  Kaposi sarcoma <.001  NHL <.001  Cervical NS Non-AIDS–defining cancers  Anal <.001  Hodgkin lymphoma  Liver NS  Lung NS  Melanoma <.05  Oropharyngeal NS  Colorectal  Breast NS  Prostate *Linear trend P value: average change in incidence rate from to and to

clinicaloptions.com/hiv Non-AIDS–Defining Cancers in Post-HAART Era Main Findings (cont’d)  Cancer incidence rates in general population over 3 observation periods –Decreased significantly for Kaposi’s sarcoma, non-Hodgkin’s lymphoma, and cervical, lung, and oropharyngeal cancers –Increased significantly for anal, colorectal, liver, and prostate cancers  Relative incidence of Kaposi’s sarcoma, non-Hodgkin’s lymphoma significantly decreased over time in HIV-infected population vs general population, whereas relative incidence of anal cancer increased significantly Patel P, et al. Ann Intern Med. 2008;148:

clinicaloptions.com/hiv Non-AIDS–Defining Cancers in Post-HAART Era Other Outcomes Patel P, et al. Ann Intern Med. 2008;148: Factors Associated With Increased Risk of Indicated Cancer Types RRP Value Acquired HIV via male-male sex  Kaposi sarcoma2.88<.001  NHL1.53<.001 Low nadir CD4+ cell count  Kaposi sarcoma8.34<.001  NHL6.03<.001  Cervical  Anal  Colorectal  Lung HBV or HCV coinfection  Liver3.63<.001

clinicaloptions.com/hiv Non-AIDS–Defining Cancers in Post-HAART Era Other Outcomes (cont’d) Patel P, et al. Ann Intern Med. 2008;148: Factors Associated with Decreased Risk of Indicated Cancer Types RRP Value HAART  Kaposi sarcoma0.61<.001  NHL0.68<.001  Cervical  Breast  Colorectal  Lung0.52<.003

clinicaloptions.com/hiv Non-AIDS–Defining Cancers in Post-HAART Era Summary of Key Conclusions  HIV-infected population had higher incidence of several types of non-AIDS–defining cancers –Relative incidence of anal cancer significantly increased over time compared with general population  HAART usage associated with decreased risk of cancer  Factors associated with increased risk of cancer –Acquired HIV via male-male sex –Low nadir CD4+ cell count  HBV or HCV coinfection Patel P, et al. Ann Intern Med. 2008;148: